Added to YB: 2025-08-11
Pitch date: 2025-08-07
NVO [bullish]
Novo Nordisk A/S
-2.68%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.86
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk's Q2 Doesn't Change My View
NVO: Down 67% YOY, stock drops 5% on earnings. Q2 revenue +13% YOY to 77B DKK, but slowing vs Q1's 20%. Op profit +25% to 72B DKK (47% margin). Obesity sales +36% US, +125% IO with Wegovy +335% IO. 900M global obesity opportunity (<1% treated). Illegal compounding hurting US sales (1M patients). Long-term price cuts likely as market expands.
Read full article (3 min)